Patents by Inventor Alastair Rae

Alastair Rae has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AMINO-SUBSTITUTED HETEROCYCLIC DERIVATIVES AS SODIUM CHANNEL INHIBITORS
    Publication number: 20180105509
    Abstract: The present invention relates to novel aminoindazolyl derivative compounds of Formula (I), the use of said compounds in treating diseases mediated by modulation of voltage-gated sodium channels in particular Nav1.7 AND to compositions containing said derivatives.
    Type: Application
    Filed: April 20, 2016
    Publication date: April 19, 2018
    Inventors: James DUFFY, Mark Stuart CHAMBERS, Alastair RAE, James OSBORNE, Isabelle Anne LEMASSON, Michael Daniel GOLDSMITH, Andrew SHARPE, Silvia FONQUERNA POU
  • FUSED IMIDAZOLE COMPOUNDS
    Publication number: 20160331757
    Abstract: The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA ?5) and act as GABAA ?5 negative allosteric modulators (GABAA ?5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA ?5 such as Alzheimer's disease.
    Type: Application
    Filed: January 30, 2015
    Publication date: November 17, 2016
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuji SAITO, Masato HIGASHINO, Soichi KAWAHARADA, Arwel LEWIS, Mark Stuart CHAMBERS, Alastair RAE, Kim Louise HIRST, Charles David HARTLEY
  • Novel compounds useful for the treatment of degenerative & inflamatory diseases
    Publication number: 20090137549
    Abstract: The present invention relates to compounds that are inhibitors of PDE1A, a phosphodiesterase that is involved in the modulation of the degradation of cartilage, joint degeneration and diseases involving such degradation and/or inflammation.
    Type: Application
    Filed: November 8, 2007
    Publication date: May 28, 2009
    Inventors: Paul John Edward, Mark Stuart Chambers, Christel Jeanne Marie Menet, Stephen Robert Fletcher, Rebecca Elizabeth Jarvis, Herve Van De Poel, Alexander Sudau, Alastair Rae, Peter Stanley Thomas